MedTrace Logo

Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

NCT01365000 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2014-10-15

No results posted yet for this study

Summary

The is an assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects.

Conditions

  • Healthy

Interventions

DRUG

NKTR118 Formulation 1

Oral dose, 25 mg

DRUG

NKTR118 Formulation 2

Oral dose, 25 mg

DRUG

NKTR118 Formulation 3

Oral dose, 25 mg

DRUG

NKTR118 Formulation 1a

Oral dose, 25 mg

DRUG

NKTR118 Formulation 3a

Oral dose, 25 mg

Sponsors & Collaborators

Principal Investigators

  • Mark Sostek, MD · AstraZeneca

  • David Mathews, MD · Quintiles, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01365000 on ClinicalTrials.gov